Citations (111)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Hui Liu, Ting Li, Hongling Yu, Xinlei Chen, Jiaqi Li, Huiwen Tan, Dejia Jia & Yerong Yu. (2023) A phase-I randomized euglycemic clamp study to demonstrate the pharmacokinetic and pharmacodynamic equivalence of an insulin degludec biosimilar (B01411) with the reference product in healthy Chinese volunteers. Expert Opinion on Investigational Drugs 32:8, pages 773-781.
Read now
Read now
Peter Novodvorský & Martin Haluzík. (2022) An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus. Expert Opinion on Drug Safety 21:3, pages 349-361.
Read now
Read now
Ulrik Pedersen-Bjergaard, Therese W. Fabricius & Birger Thorsteinsson. (2021) Synthetic long-acting insulin analogs for the management of type 1 diabetes: an update. Expert Opinion on Pharmacotherapy 22:16, pages 2251-2259.
Read now
Read now
Eveline Lefever, Joke Vliebergh & Chantal Mathieu. (2021) Improving the treatment of patients with diabetes using insulin analogues: current findings and future directions. Expert Opinion on Drug Safety 20:2, pages 155-169.
Read now
Read now
Charline Bottinelli, Nathalie Cartiser, Fabien Bévalot, Laurent Fanton & Jérôme Guitton. (2020) Is insulin intoxication still the perfect crime? Analysis and interpretation of postmortem insulin: review and perspectives in forensic toxicology. Critical Reviews in Toxicology 50:4, pages 324-347.
Read now
Read now
Marc Rendell. (2019) Premix insulins in type 1 diabetes: the coming of degludec/aspart. Expert Opinion on Drug Metabolism & Toxicology 15:4, pages 341-348.
Read now
Read now
Marcus Hompesch, Dhiren K. Patel, James R. LaSalle & Geremia B. Bolli. (2019) Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes. Postgraduate Medicine 131:2, pages 117-128.
Read now
Read now
Oppel Bw Greeff, Jacob John van Tonder, Kershlin Naidu, Alicia McMaster, Alet van Tonder & Rashem Mothilal. (2018) A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part two: Insulin degludec vs. insulin glargine U300. Journal of Endocrinology, Metabolism and Diabetes of South Africa 23:2, pages 46-51.
Read now
Read now
Edurne Lecumberri, Maite Ortega, Marta Iturregui, José Antonio Quesada, Clotilde Vázquez & Domingo Orozco. (2018) Quality-of-life and treatment satisfaction in actual clinical practice of patients with Type 1 diabetes mellitus (T1DM) and hypoglycemia treated with insulin degludec. Current Medical Research and Opinion 34:6, pages 1053-1059.
Read now
Read now
Oppel BW Greeff, Jacob John van Tonder, Kershlin Naidu, Alicia McMaster, Alet van Tonder & Rashem Mothilal. (2018) A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part one: The principles of glucose clamp studies. Journal of Endocrinology, Metabolism and Diabetes of South Africa 23:1, pages 17-21.
Read now
Read now
Marc Rendell. (2017) United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes. Drug Design, Development and Therapy 11, pages 1209-1220.
Read now
Read now
Rosemarie Lajara, Eda Cengiz & Robert J. Tanenberg. (2017) The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes. Current Medical Research and Opinion 33:6, pages 1045-1055.
Read now
Read now
Louise Vedtofte, Filip K. Knop & Tina Vilsbøll. (2017) Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes. Expert Opinion on Drug Safety 16:3, pages 387-396.
Read now
Read now
Articles from other publishers (98)
Thomas Haak, Stefan Gölz, Andreas Fritsche, Martin Füchtenbusch, Thorsten Siegmund, Elisabeth Schnellbächer, Harald H. Klein, Til Uebel & Diana Droßel. (2023) Therapie des Typ-1-Diabetes – Kurzfassung der S3-Leitlinie (AWMF-Registernummer: 057-013; 4. Auflage 2018). Diabetologie und Stoffwechsel 18:S 02, pages S136-S147.
Crossref
Crossref
Thomas Kjeldsen, Asser Sloth Andersen, František Hubálek, Eva Johansson, Frederik Flindt Kreiner, Gerd Schluckebier & Peter Kurtzhals. (2023) Molecular engineering of insulin for recombinant expression in yeast. Trends in Biotechnology.
Crossref
Crossref
Steven Edelman, Jennifer Goldman, Daniel C. Malone, Ronald Preblick, Kovida Munaga, Xuan Li, Jasvinder Gill & Sumana Gangi. (2023) Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100). Clinical Diabetes 41:3, pages 425-434.
Crossref
Crossref
Thomas Haak, Stefan Gölz, Andreas Fritsche, Martin Füchtenbusch, Thorsten Siegmund, Elisabeth Schnellbächer, Harald H. Klein, Til Uebel & Diana Droßel. (2023) Therapie des Typ-1-DiabetesTreatment of type 1 diabetes. Die Diabetologie 19:5, pages 647-657.
Crossref
Crossref
Rory J McCrimmon. (2023) ONWARDS and upwards for basal insulin. The Lancet 401:10392, pages 1904-1905.
Crossref
Crossref
Linda C. A. Drenthen, Mandala Ajie, Evertine J. Abbink, Laura Rodwell, Dick H. J. Thijssen, Cees J. Tack & Bastiaan E. de Galan. (2023) No insulin degludec dose adjustment required after aerobic exercise for people with type 1 diabetes: the ADREM study. Diabetologia 66:6, pages 1035-1044.
Crossref
Crossref
Laura M. Nally, Jennifer L. Sherr, Eileen Tichy, Kate Weyman, Andrea Urban, Veronika Shabanova, Sarah McCollum, Amy Steffen, William V. Tamborlane & Michelle Van Name. (2023) Impact of school‐supervised ultra‐long‐acting basal insulin injections on ketosis in youth with T1D and elevated haemoglobin A1c: A pilot study. Diabetic Medicine.
Crossref
Crossref
Tim Heise, Jenny Chien, John M. Beals, Charles Benson, Oliver Klein, Julie S. Moyers, Axel Haupt & Edward John Pratt. (2023) Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once‐weekly dosing for the treatment of patients with diabetes. Diabetes, Obesity and Metabolism 25:4, pages 1080-1090.
Crossref
Crossref
Jayabharathi Vaidyanathan, Yow‐Ming C. Wang, Doanh Tran & Shirley K. Seo. (2022) Leveraging Clinical Pharmacology Data to Assess Biosimilarity and Interchangeability of Insulin Products. Clinical Pharmacology & Therapeutics 113:4, pages 794-802.
Crossref
Crossref
Philip Home. (2023) Making sense of weekly insulins. The Lancet Diabetes & Endocrinology 11:3, pages 140-141.
Crossref
Crossref
Ting Li, Hui Liu, Songlin Li, Hongling Yu, Jiaqi Li, Huiwen Tan & Yerong Yu. (2023) The Effect of BMI on Pharmacokinetic and Pharmacodynamic Parameters of Insulin Degludec: Results from an Euglycemic Glucose Clamp Study. Clinical Pharmacokinetics 62:3, pages 449-456.
Crossref
Crossref
Tadej Battelino, Thomas Danne, Steve V. Edelman, Pratik Choudhary, Eric Renard, Jukka Westerbacka, Bhaswati Mukherjee, Valerie Pilorget, Mathieu Coudert & Richard M. Bergenstal. (2022)
C
ontinuous glucose monitoring‐based
time‐in‐range
using insulin glargine 300 units/
ml
versus insulin degludec 100 units/
ml
in type 1 diabetes: The
head‐to‐head
randomized controlled
InRange
trial
. Diabetes, Obesity and Metabolism 25:2, pages 545-555.
Crossref
Crossref
Thomas Haak, Stefan Gölz, Andreas Fritsche, Martin Füchtenbusch, Thorsten Siegmund, Elisabeth Schnellbächer, Harald H. Klein, Til Uebel & Diana Droßel. (2023) Therapie des Typ-1-Diabetes. Diabetes aktuell 21:01, pages 30-42.
Crossref
Crossref
María Soledad Ruiz de Adana, Marta Elena Domínguez, Virginia Morillas, Natalia Colomo, Rosario Vallejo-Mora, Mercedes Guerrero, Eva García-Escobar, Mónica Carreira, Yanina Romero-Zerbo, Francisca Linares, Isabel González-Mariscal, Francisco Javier Bermúdez-Silva, Gabriel Olveira & Gemma Rojo-Martínez. (2023) Efficacy and safety of basal insulin degludec 100 IU/mL versus glargine 300 IU/mL for type 1 diabetes: The single-center INEOX randomized controlled trial. Diabetes Research and Clinical Practice 196, pages 110238.
Crossref
Crossref
Elisabeth R Mathiesen, Amra Ciric Alibegovic, Rosa Corcoy, Fidelma Dunne, Denice S Feig, Moshe Hod, Ting Jia, Balamurali Kalyanam, Soumitra Kar, Alexandra Kautzky-Willer, Cassio Marchesini, Rustam D Rea & Peter Damm. (2023) Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial. The Lancet Diabetes & Endocrinology 11:2, pages 86-95.
Crossref
Crossref
Yufei Pan, Xinyang Zhou & Zhenjun Yang. 2023. Nucleic Acids in Medicinal Chemistry and Chemical Biology. Nucleic Acids in Medicinal Chemistry and Chemical Biology
373
427
.
Niels Rode Kristensen & Henrik Agersø. (2022) Dose/exposure–response modeling in dose titration trials: Overcoming the titration paradox. CPT: Pharmacometrics & Systems Pharmacology 11:12, pages 1592-1603.
Crossref
Crossref
Thomas Haak, Stefan Gölz, Andreas Fritsche, Martin Füchtenbusch, Thorsten Siegmund, Elisabeth Schnellbächer, Harald H. Klein, Til Uebel & Diana Droßel. (2022) Therapie des Typ-1-Diabetes. Diabetologie und Stoffwechsel 17:S 02, pages S133-S144.
Crossref
Crossref
Claudio Maffeis & Ivana Rabbone. (2022) Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes. Pediatric Drugs 24:5, pages 499-512.
Crossref
Crossref
Yiya Wang, Ying Zhou, Juefang Ding, Xianjing Li, Fengxue Guo, Jianfei Zhang & Li Ding. (2022) Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus® in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints. Frontiers in Pharmacology 13.
Crossref
Crossref
Thomas Haak, Stefan Gölz, Andreas Fritsche, Martin Füchtenbusch, Thorsten Siegmund, Elisabeth Schnellbächer, Harald H. Klein, Til Uebel & Diana Droßel. (2022) Therapie des Typ-1-DiabetesTherapy of type 1 diabetes. Die Diabetologie 18:5, pages 612-622.
Crossref
Crossref
Eugene E WrightJrJrDaniel C MaloneJennifer M TrujilloJasvinder GillSamuel HuseXuan LiFang Liz ZhouRon PreblickTimothy Reid. (2022) Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin. Journal of Managed Care & Specialty Pharmacy, pages 1-12.
Crossref
Crossref
Han Na Jang, Ye Seul Yang, Tae Jung Oh, Bo Kyung Koo, Seong Ok Lee, Kyong Soo Park, Hak Chul Jang & Hye Seung Jung. (2021) Low fasting glucose‐to‐estimated average glucose ratio was associated with superior response to insulin degludec/aspart compared with basal insulin in patients with type 2 diabetes. Journal of Diabetes Investigation 13:1, pages 85-93.
Crossref
Crossref
Julio Rosenstock & Stefano Del Prato. (2022) Basal weekly insulins: the way of the future!. Metabolism 126, pages 154924.
Crossref
Crossref
Yi Tao, Mingxue Zhu, Junliang Pu, Peilin Zhang, Lei Wan & Chengyong Tang. (2021) Reduction in C-Peptide Levels and Influence on Pharmacokinetics and Pharmacodynamics of Insulin Preparations: How to Conduct a High-Quality Euglycemic Clamp Study. Frontiers in Pharmacology 12.
Crossref
Crossref
Chantal Mathieu, Pieter-Jan Martens & Roman Vangoitsenhoven. (2021) One hundred years of insulin therapy. Nature Reviews Endocrinology 17:12, pages 715-725.
Crossref
Crossref
Andrea C. Tricco, Huda M. Ashoor, Jesmin Antony, Zachary Bouck, Myanca Rodrigues, Ba’ Pham, Paul A. Khan, Vera Nincic, Nazia Darvesh, Fatemeh Yazdi, Marco Ghassemi, John D. Ivory, Areti Angeliki Veroniki, Catherine H. Yu, Lorenzo Moja & Sharon E. Straus. (2021) Comparative Efficacy and Safety of Ultra-Long-Acting, Long-Acting, Intermediate-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: a Systematic Review and Network Meta-Analysis. Journal of General Internal Medicine 36:8, pages 2414-2426.
Crossref
Crossref
Thomas Haak, Stefan Gölz, Andreas Fritsche, Martin Füchtenbusch, Thorsten Siegmund, Elisabeth Schnellbächer, Harald H. Klein, Til Uebel & Diana Droßel. (2021) Therapie des Typ-1-DiabetesTherapy of type 1 diabetes. Der Diabetologe 17:4, pages 411-421.
Crossref
Crossref
Federico Boscari & Angelo Avogaro. (2021) Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives. Reviews in Endocrine and Metabolic Disorders 22:2, pages 217-240.
Crossref
Crossref
Stewart B. Harris, Olubukola Ajala, Basel Bari, Joanne Liutkus, Jina Hahn, Oliver Martyn & Deborah Zwicker. (2021) Evaluating the Effectiveness of Switching to Insulin Degludec from Other Basal Insulins in a Real-World Canadian Population with Type 1 or Type 2 Diabetes: The CAN-TREAT Study. Diabetes Therapy.
Crossref
Crossref
Kazuma Ogiso, Nobuyuki Koriyama, Takahiko Obo, Akinori Tokito & Yoshihiko Nishio. (2020) Basal insulin ameliorates post-breakfast hyperglycemia via suppression of post-breakfast proinsulin/C-peptide ratio and fasting serum free fatty acid levels in patients with type 2 diabetes. Diabetology International 12:2, pages 161-170.
Crossref
Crossref
Tevfik Demir, Serap Turan, Kursad Unluhizarci, Oya Topaloglu, Tufan Tukek & Dilek Gogas Yavuz. (2021) Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns. Frontiers in Endocrinology 12.
Crossref
Crossref
Luigi Laviola, Francesca Porcellati, Daniela Bruttomesso, Monica Larosa, Maria Chiara Rossi & Antonio Nicolucci. (2020) Comparative Effectiveness of Switching From First-Generation Basal Insulin to Glargine 300 U/ml or Degludec 100 U/ml in Type 1 Diabetes: The RESTORE-1 Study. Diabetes Therapy 12:2, pages 509-525.
Crossref
Crossref
Hiroshi Miura, Kazuhiko Sakaguchi, Natsu Otowa‐Suematsu, Tomoko Yamada, Anna So, Hisako Komada, Yuko Okada, Yushi Hirota, Yoshikazu Tamori & Wataru Ogawa. (2020)
Effects of insulin degludec and insulin glargine
U300
on glycaemic stability in individuals with type 1 diabetes: A multicentre, randomized controlled crossover study
. Diabetes, Obesity and Metabolism 22:12, pages 2356-2363.
Crossref
Crossref
Luigi F. Meneghini, Sean D. Sullivan, Gerry Oster, Robert Busch, Anna M. G. Cali, Arnaud Dauchy, Jasvinder Gill & Timothy S. Bailey. (2020)
A pragmatic randomized clinical trial of insulin glargine 300 U/
mL
vs first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 6‐month outcomes of the
ACHIEVE
Control study
. Diabetes, Obesity and Metabolism 22:11, pages 2004-2012.
Crossref
Crossref
Vincent Woo, Lori Berard & Robert Roscoe. (2020) Understanding the Clinical Profile of Insulin Degludec, the Latest Basal Insulin Approved for Use in Canada: a Narrative Review. Diabetes Therapy 11:11, pages 2539-2553.
Crossref
Crossref
Joseph Tibaldi, Max E. Mercado & Jodi Strong. (2020) How Effective Is the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) in Different Patient Populations, and When Should It Be Used in Clinical Practice?. Clinical Diabetes 38:4, pages 339-347.
Crossref
Crossref
Irl B Hirsch, Rattan Juneja, John M Beals, Caryl J Antalis & Eugene E WrightJr.Jr.. (2020) The Evolution of Insulin and How it Informs Therapy and Treatment Choices. Endocrine Reviews 41:5, pages 733-755.
Crossref
Crossref
Thomas Haak, Stefan Gölz, Andreas Fritsche, Martin Füchtenbusch, Thorsten Siegmund, Elisabeth Schnellbächer, Harald H. Klein, Til Uebel & Diana Droßel. (2020) Therapie des Typ-1-Diabetes – Kurzfassung der S3-Leitlinie (AWMF-Registernummer: 057-013; 2. Auflage). Diabetologie und Stoffwechsel 15:S 01, pages S40-S50.
Crossref
Crossref
Alice Cheng, Timothy S. Bailey, Didac Mauricio & Ronan Roussel. (2020)
Insulin glargine 300 U/
mL
and insulin degludec: A review of the current evidence comparing these two second‐generation basal insulin analogues
. Diabetes/Metabolism Research and Reviews 36:7.
Crossref
Crossref
Tadej BattelinoSteven EdelmanRimei NishimuraRichard M. Bergenstal. (2020) Comparison of Second-Generation Basal Insulin Analogs: A Review of the Evidence from Continuous Glucose Monitoring. Diabetes Technology & Therapeutics.
Crossref
Crossref
Christine Faust, Christian Ochs, Marcus Korn, Ulrich Werner, Jennifer Jung, Werner Dittrich, Werner Schiebler, Rolf Schauder, Ercole Rao & Thomas Langer. (2020) Production of a novel heterodimeric two-chain insulin-Fc fusion protein. Protein Engineering, Design and Selection 33.
Crossref
Crossref
Michele SchiavonRoberto VisentinClemens GiegerichJochen SieberChiara Dalla ManClaudio CobelliThomas Klabunde. (2020)
In Silico
Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes
. Diabetes Technology & Therapeutics 22:8, pages 553-561.
Crossref
Crossref
Thomas Haak, Stefan Gölz, Andreas Fritsche, Martin Füchtenbusch, Thorsten Siegmund, Elisabeth Schnellbächer, Harald H. Klein, Til Uebel & Diana Droßel. (2020) Therapie des Typ-1-DiabetesTherapy of type 1 diabetes. Der Diabetologe 16:3, pages 254-265.
Crossref
Crossref
S. Misra & C. Mathieu. (2019) Are newer insulin analogues better for people with Type 1 diabetes?. Diabetic Medicine 37:4, pages 522-531.
Crossref
Crossref
Athena Philis-Tsimikas, David C. Klonoff, Kamlesh Khunti, Harpreet S. Bajaj, Lawrence A. Leiter, Melissa V. Hansen, Lone N. Troelsen, Steen Ladelund, Simon Heller & Thomas R. Pieber. (2020) Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. Diabetologia 63:4, pages 698-710.
Crossref
Crossref
L. Meneghini, A. Doshi, D. Gouet, T. Vilsbøll, K. Begtrup, P. Őrsy, M. F. Ranthe & I. Lingvay. (2019)
Insulin degludec/liraglutide (
ID
egLira) maintains glycaemic control and improves clinical outcomes, regardless of pre‐trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin
. Diabetic Medicine 37:2, pages 267-276.
Crossref
Crossref
Thomas R. Pieber, Lars Bardtrum, Joakim Isendahl, Lily Wagner & Rimei Nishimura. (2020) Commentary to “Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec” by Kawaguchi et al. Diabetes Therapy 2019. Diabetes Therapy 11:2, pages 561-567.
Crossref
Crossref
Alan J. Garber, Yehuda Handelsman, George Grunberger, Daniel Einhorn, Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Michael A. Bush, Ralph A. DeFronzo, Jeffrey R. Garber, W.Timothy Garvey, Irl B. Hirsch, Paul S. Jellinger, Janet B. McGill, Jeffrey I. Mechanick, Leigh Perreault, Paul D. Rosenblit, Susan Samson & Guillermo E. Umpierrez. (2020) Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary. Endocrine Practice 26:1, pages 107-139.
Crossref
Crossref
Helena W. Rodbard & David Rodbard. (2020) Biosynthetic Human Insulin and Insulin Analogs. American Journal of Therapeutics 27:1, pages e42-e51.
Crossref
Crossref
Yuji Kawaguchi, Jun Sawa, Chie Hamai, Yuri Nishimura & Yasuro Kumeda. (2019) Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy). Journal of Diabetes Investigation 10:6, pages 1527-1536.
Crossref
Crossref
D.R. Owens, T. S Bailey, C.G. Fanelli, J.-F. Yale & G.B. Bolli. (2019) Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) – a review of evidence and clinical interpretation. Diabetes & Metabolism 45:4, pages 330-340.
Crossref
Crossref
M. Ehren & H. H. Klein. (2019) Insulintherapie – neue InsulinanalogaInsulin therapy—new insulin analogues. Der Internist 60:9, pages 887-894.
Crossref
Crossref
Nandu Thalange, Torben Biester & Thomas Danne. (2019) Clinical Use of Degludec in Children and Adolescents with T1D: A Narrative Review with Fictionalized Case Reports. Diabetes Therapy 10:4, pages 1219-1237.
Crossref
Crossref
Richard E. Pratley, Scott S. Emerson, Edward Franek, Matthew P. Gilbert, Steven P. Marso, Darren K. McGuire, Thomas R. Pieber, Bernard Zinman, Charlotte T. Hansen, Melissa V. Hansen, Thomas Mark, Alan C. Moses & John B. Buse. (2019) Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). Diabetes, Obesity and Metabolism 21:7, pages 1625-1633.
Crossref
Crossref
David Russell‐Jones, Arnaud Dauchy, Elías Delgado, George Dimitriadis, Hans A. Frandsen, Luiza Popescu, Bernd Schultes, Krzysztof Strojek, Mireille Bonnemaire, Aude Roborel de Climens & Melanie Davies. (2019) Take Control: A randomized trial evaluating the efficacy and safety of self‐ versus physician‐managed titration of insulin glargine 300 U/mL in patients with uncontrolled type 2 diabetes. Diabetes, Obesity and Metabolism 21:7, pages 1615-1624.
Crossref
Crossref
Alice Y. Y. Cheng, Dhiren K. Patel, Timothy S. Reid & Kathleen Wyne. (2019) Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different. Advances in Therapy 36:5, pages 1018-1030.
Crossref
Crossref
Tim Heise, Grégory Meiffren, Bertrand Alluis, Cyril Seroussi, Aymeric Ranson, Jorge Arrubla, José Correia, Martin Gaudier, Olivier Soula, Rémi Soula, J. Hans DeVries, Oliver Klein & Bruce Bode. (2019) BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. Diabetes, Obesity and Metabolism 21:4, pages 1066-1070.
Crossref
Crossref
C. Lualdi, A. Silverii, I. Dicembrini, L. Pala, M. Monami & E. Mannucci. (2018) Adjustment of insulin doses when switching from glargine 100 U/ml or detemir to degludec: an observational study. Journal of Endocrinological Investigation 42:3, pages 319-326.
Crossref
Crossref
Thomas Haak, Stefan Gölz, Andreas Fritsche, Martin Füchtenbusch, Thorsten Siegmund, Elisabeth Schnellbächer, Harald H. Klein, Til Uebel & Diana Droßel. (2019) Therapie des Typ-1-DiabetesTherapy of type 1 diabetes. Der Diabetologe 15:2, pages 135-145.
Crossref
Crossref
Arun K. Sharma, Gaurav Taneja, Ashish Kumar, Megha Sahu, Gunjan Sharma, Asim Kumar, Satish Sardana & Aakash Deep. (2019) Insulin analogs: Glimpse on contemporary facts and future prospective. Life Sciences 219, pages 90-99.
Crossref
Crossref
Sudesna Chatterjee, Kamlesh Khunti & Melanie J. Davies. (2019) Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes. Drugs 79:2, pages 173-186.
Crossref
Crossref
Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Zachary T. Bloomgarden, Michael A. Bush, Samuel Dagogo-Jack, Ralph A. DeFronzo, Daniel Einhorn, Vivian A. Fonseca, Jeffrey R. Garber, W. Timothy Garvey, George Grunberger, Yehuda Handelsman, Irl B. Hirsch, Paul S. Jellinger, Janet B. McGill, Jeffrey I. Mechanick, Paul D. Rosenblit & Guillermo E. Umpierrez. (2019) Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary. Endocrine Practice 25:1, pages 69-101.
Crossref
Crossref
Jun Suzuki, Tadashi Yamakawa, Mari Oba, Jo Nagakura, Erina Shigematsu, Haruka Tamura, Kenichiro Takahashi, Yoshihisa Okamoto, Rika Sakamoto, Minori Shinoda, Tatsuro Takano, Kazuaki Kadonosono & Yasuo Terauchi. (2019) Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an open-label, randomized controlled study. Endocrine Journal 66:11, pages 971-982.
Crossref
Crossref
Jessica Schmitt & Mary Lauren Scott. (2019) Insulin Degludec in Adolescents with Type 1 Diabetes: Is Newer Better? – A Retrospective Self-Control Case Series in Adolescents with a History of Diabetic Ketoacidosis. Hormone Research in Paediatrics 92:3, pages 179-185.
Crossref
Crossref
Cristina Bianchi, Michele Aragona, Cosimo Rodia, Walter Baronti, Giovanni de Gennaro, Alessandra Bertolotto & Stefano Del Prato. (2019) Freestyle Libre trend arrows for the management of adults with insulin-treated diabetes: A practical approach. Journal of Diabetes and its Complications 33:1, pages 6-12.
Crossref
Crossref
A. Philis-Tsimikas, K. Astamirova, Y. Gupta, A. Haggag, D. Roula, B.A. Bak, E.G. Fita, A.M. Nielsen & T. Demir. (2019) Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 147, pages 157-165.
Crossref
Crossref
Tim Heise, Sascha Heckermann & J. Hans DeVries. (2018) Variability of insulin degludec and glargine 300 U/mL: A matter of methodology or just marketing?. Diabetes, Obesity and Metabolism 20:9, pages 2051-2056.
Crossref
Crossref
Reinhard H.A. Becker. (2018) In response to: Heise T, Nørskov M, Nosek L, Kaplan K, Famulla S and Haahr H. L. (2017) Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared to insulin glargine U300 in type 1 diabetes. Diabetes Obes Metab. 20. Diabetes, Obesity and Metabolism 20:8, pages 2043-2047.
Crossref
Crossref
Yana Anfinogenova, Elena V. Grakova, Maria Shvedova, Kristina V. Kopieva, Alexander T. Teplyakov & Sergey V. Popov. (2017) Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure. Heart Failure Reviews 23:3, pages 481-497.
Crossref
Crossref
Vanita R. Aroda, Joseph R. Arulandu & Anthony J. Cannon. (2018) Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?. Clinical Diabetes 36:2, pages 138-147.
Crossref
Crossref
Tim Heise, Kadriye Kaplan & Hanne L. Haahr. (2017) Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies. Journal of Diabetes Science and Technology 12:2, pages 356-363.
Crossref
Crossref
Michael F. Crutchlow, John S. Palcza, Kate M. Mostoller, Chantal D. Mahon, April M. Barbour, Michael C. Marcos, Yang Xu, Elaine Watkins, Linda Morrow & Marcus Hompesch. (2018) Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects. Diabetes, Obesity and Metabolism 20:2, pages 400-408.
Crossref
Crossref
J. Uchida, Y. Oikawa, T. Katsuki, H. Takeda, A. Shimada & T. Kawai. (2018) Insulin degludec overdose may lead to long-lasting hypoglycaemia through its markedly prolonged half-life. Diabetic Medicine 35:2, pages 277-280.
Crossref
Crossref
T.S. Bailey, J. Pettus, R. Roussel, W. Schmider, M. Maroccia, N. Nassr, O. Klein, G.B. Bolli & R. Dahmen. (2018) Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes. Diabetes & Metabolism 44:1, pages 15-21.
Crossref
Crossref
Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Zachary T. Bloomgarden, Michael A. Bush, Samuel Dagogo-Jack, Ralph A. DeFronzo, Daniel Einhorn, Vivian A. Fonseca, Jeffrey R. Garber, W. Timothy Garvey, George Grunberger, Yehuda Handelsman, Irl B. Hirsch, Paul S. Jellinger, Janet B. McGill, Jeffrey I. Mechanick, Paul D. Rosenblit & Guillermo E. Umpierrez. (2018) Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. Endocrine Practice 24:1, pages 91-121.
Crossref
Crossref
Lisa Michel. (2017) Session One: Basal Insulins: Still Innovating After All These Years. EMJ Diabetes, pages 38-45.
Crossref
Crossref
Yoshiyuki Hamamoto, Sachiko Honjo, Kanta Fujimoto, Shinsuke Tokumoto, Hiroki Ikeda, Yoshiharu Wada & Hiroyuki Koshiyama. (2017) Basal and Bolus Insulin Dose Changes after Switching Basal Insulin to Insulin Degludec in Patients with Type 1 Diabetes Mellitus: A Pilot Study. Clinical Drug Investigation 37:9, pages 845-852.
Crossref
Crossref
Yoshimasa Aso, Kunihiro Suzuki, Yasuko Chiba, Minoru Sato, Nobuya Fujita, Yoshihisa Takada, Shunichi Murano & Hisamoto Kuroda. (2017) Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I’D GOT trial. Diabetes Research and Clinical Practice 130, pages 237-243.
Crossref
Crossref
Virginia Valentine, Jennifer Goldman & Jay H. Shubrook. (2017) Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes. Diabetes Therapy 8:4, pages 739-752.
Crossref
Crossref
Tim Heise, Marianne Nørskov, Leszek Nosek, Kadriye Kaplan, Susanne Famulla & Hanne L. Haahr. (2017) Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes, Obesity and Metabolism 19:7, pages 1032-1039.
Crossref
Crossref
Chantal Mathieu, Pieter Gillard & Katrien Benhalima. (2017) Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nature Reviews Endocrinology 13:7, pages 385-399.
Crossref
Crossref
Hanne Haahr, Edmond G. Fita & Tim Heise. (2016) A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use. Clinical Pharmacokinetics 56:4, pages 339-354.
Crossref
Crossref
Jacqueline L. Olin & Kira B. Harris. (2017) Expanded Basal Insulin Options for Type 2 Diabetes Mellitus. The Journal for Nurse Practitioners 13:3, pages 210-215.
Crossref
Crossref
Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Zachary T. Bloomgarden, Michael A. Bush, Samuel Dagogo-Jack, Ralph A. DeFronzo, Daniel Einhorn, Vivian A. Fonseca, Jeffrey R. Garber, W. Timothy Garvey, George Grunberger, Yehuda Handelsman, Irl B. Hirsch, Paul S. Jellinger, Janet B. McGill, Jeffrey I. Mechanick, Paul D. Rosenblit & Guillermo E. Umpierrez. (2017) Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm – 2017 Executive Summary. Endocrine Practice 23:2, pages 207-238.
Crossref
Crossref
Jennifer L. Sherr, Eda Cengiz, Michelle A. Van Name, Stuart A. Weinzimer & William V. Tamborlane. 2017. Textbook of Diabetes. Textbook of Diabetes
985
999
.
Tim Heise & Chantal Mathieu. (2017) Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes, Obesity and Metabolism 19:1, pages 3-12.
Crossref
Crossref
Helle Linnebjerg, Eric Chen Quin Lam, Xin Zhang, Mary E. Seger, David Coutant, Laiyi Chua, Christoph Kapitza & Tim Heise. (2017) Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus. Diabetes, Obesity and Metabolism 19:1, pages 33-39.
Crossref
Crossref
Jennifer Goldman & John R. WhiteJrJr. (2016) Advances in Basal Insulin Therapy. Journal of Pharmacy Technology 32:6, pages 260-268.
Crossref
Crossref
Alan J. Garber. (2016) The History of Insulin Technology: A Brief Review of the Updates in Basal Insulin Therapy Through the Years. Endocrine Practice 22, pages 7-9.
Crossref
Crossref
Bruce Bode. (2016) When and how to Use A Glp-1 ra With Long- or Ultralong-Acting Basal Insulin in T2Dm. Endocrine Practice 22, pages 14-22.
Crossref
Crossref
Guillermo E. Umpierrez. (2016) When and how to Use Prandial Insulin with Ultralong-Acting Basal Insulin in T2Dm. Endocrine Practice 22, pages 12-14.
Crossref
Crossref
Alan J. Garber. (2016) When and how to Use Ultralong-Acting Basal Insulin in T2Dm. Endocrine Practice 22, pages 9-12.
Crossref
Crossref
Hanne Haahr, Tomio Sasaki, Lars Bardtrum & Ippei Ikushima. (2016) Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects. Journal of Diabetes Investigation 7:4, pages 574-580.
Crossref
Crossref
Ippei Ikushima, Kohei Kaku, Koichi Hirao, Lars Bardtrum & Hanne Haahr. (2015) Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients. Journal of Diabetes Investigation 7:2, pages 270-275.
Crossref
Crossref
T. Heise, S. C. Bain, R. M. Bracken, E. Zijlstra, L. Nosek, K. Stender‐Petersen, R. Rabøl, E. Rowe & H. L. Haahr. (2015) Similar risk of exercise‐related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross‐over trial. Diabetes, Obesity and Metabolism 18:2, pages 196-199.
Crossref
Crossref
M. Davies, T. Sasaki, J. L. Gross, G. Bantwal, Y. Ono, T. Nishida, D. Tojjar & H. Seino. (2016) Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial. Diabetes, Obesity and Metabolism 18:1, pages 96-99.
Crossref
Crossref
Francesca Porcellati, Paola Lucidi, Geremia B. Bolli & Carmine G. Fanelli. (2015) How to Accurately Establish Pharmacokinetics/Pharmacodynamics of Long-Acting Insulins in Humans: Relevance to Biosimilar Insulins. Diabetes Care 38:12, pages 2237-2240.
Crossref
Crossref